Risk factors for developing thromboembolic complications in oncological patients (a literature review)
AbstractOncological patients are typically prone to the development of thromboembolic complications significantly worsening the general prognosis of the disease. Therefore, determining the probability of the onset and prevention of these complications remains an important practical task.
This literature review presents the data of foreign and Russian authors on the major risk factors for developing venous thromboembolic complications in oncological patients, also giving characteristics of the main biochemical markers of the ongoing processes and intrinsic thereto alterations. This is followed by reflecting the incidence of thromboembolic events depending on the type, localization, incidence, degree of differentiation of malignant neoplasms, the presence or absence of concomitant diseases in patients, as well as the main demographic criteria associated with this pathology, Also analyzed herein is the effect of some chemotherapeutic drugs used as adjuvant and neoadjuvant therapy on the onset of thrombotic events. Next comes the information on the effect of radiation methods of treatment on the development of thromboses and thromboembolisms in oncological patients. Additionally demonstrated is the relationship of thromboembolic processes in patients suffering from malignant neoplasms with surgical interventions and placement of central venous catheters.
Keywords:thrombosis; venous thromboembolic complications; risk factors; oncological diseases; thrombus formation
Funding. The study had no financial support.
Conflict of interest. The authors declare no conflict of interest.
Authors’ contribution. Study conception and design – Kulikova A.N.; data collection and handling – Tonka-
cheva A.A.; statistical processing – Tonkacheva A.A.; draft manuscript preparation – Tonkacheva A.A.; manuscript revision – Kulikova A.N.
For citation: Kulikova A.N., Tonkacheva A.A. Risk factors for developing thromboembolic complications in oncological patients (a literature review). Angiology and Vascular Surgery. 2022; 28 (4): 119–25. DOI: https://doi.org/10.33029/1027-6661-2022-28-4-119-125 (in Russian)
References
1. Ohashi Y., Ikeda M., Kunitoh H., et al. Venous thromboembolism in cancer patients: report of baseline data from the multicentre, prospective Cancer-VTE Registry. Japanese Journal of Clinical Oncology. 2020; 50 (11): 1246–1253. DOI: https://doi.org/10.1093/jjco/hyaa112
2. Puurunen M.K., Gona P.N., Larson M.G., et al. Epidemiology of venous thromboembolism in the Framingham Heart Study. Thrombosis Research. 2016; 145: 27–33. DOI: https://doi.org/10.1016/j.thromres.2016.06.033
3. Practical recommendations for the prevention and treatment of thromboembolic complications in cancer patients. Malignant tumours: Practical recommendations RUSSCO. 2019; 9 (3): 668–677. (in Russian)
4. Martín M.A.J., Ortega I., Font C., et al. Multivariable clinical-genetic risk model for predicting venous thromboembolic events in patients with cancer. British Journal of Cancer. 2018; 118 (8): 1056–1061. DOI: https://doi.org/10.1038/s41416-018-0027-8
5. Khorana A.A., Carrier M., Garcia D.A., Lee A.Y. Guidance for the prevention and treatment of cancer-associated venous thromboembolism. Journal of Thrombosis and Thrombolysis. 2016; 41 (1): 81–91. DOI: https://doi.org/10.1007/s11239-015-1313-4
6. Rautou P.E., Mackman N. Microvesicles as risk markers for venous thrombosis. Expert Review of Hematology. 2013; 6 (1): 91–101. DOI: https://doi.org/10.1586/ehm.12.74
7. Königsbrügge O., Pabinger I., Ay C. Risk factors for venous thromboembolism in cancer: novel findings from the Vienna Cancer and Thrombosis Study (CATS). Thrombosis Research. 2014; 133 (2): 39–43. DOI: https://doi.org/10.1016/S0049-3848(14)50007-2
8. Demers M., Wagner D.D. Neutrophil extracellular traps: a new link to cancer-associated thrombosis and potential implications for tumor progression. Oncoimmunology. 2013; 2 (2): 22946. DOI: https://doi.org/10.4161/onci.22946
9. Pabinger I., Thaler J., Ay C. Biomarkers for prediction of venous thromboembolism in cancer. Blood. 2013; 122 (12): 2011–2018. DOI: https://doi.org/10.1182/blood-2013-04-460147
10. Watson H.G., Keeling D.M., Laffan M., et al. Guideline on aspects of cancer-related venous thrombosis. British Journal of Haematology. 2015; 170 (5): 640–648. DOI: https://doi.org/10.1111/bjh.12107
11. Horsted F., West J., Grainge M. Risk of venous thromboembolism in patients with cancer: a systematic review and meta-analysis. PLOS Medicine. 2012; 9 (7): 1001275. DOI: https://doi.org/10.1371/journal.pmed.1001275
12. Walker A.J., Card T.R., West J., et al. Incidence of venous thromboembolism in patients with cancer – a cohort study using linked United Kingdom databases. European Journal of Cancer. 2013; 49 (6): 1404–1413. DOI: https://doi.org/10.1016/j.ejca.2012.10.021
13. Abdel-Razeq H., Mansour A., Saadeh S.S., et al. The application of current proposed venous thromboembolism risk assessment model for ambulatory patients with cancer. Clinical and Applied Thrombosis/Hemostasis. 2018; 24 (3): 429–433. DOI: https://doi.org/10.1177/1076029617692880
14. Timp J.F., Braekkan S.K., Versteeg H.H., Cannegieter S.C. Epidemiology of cancer-associated venous thrombosis. Blood. 2013; 122 (10): 1712–1723. DOI: https://doi.org/10.1182/blood-2013-04-460121
15. Gade I.L., Braekkan S.K., Naess I.A., et al. The impact of initial cancer stage on the incidence of venous thromboembolism: the Scandinavian Thrombosis and Cancer (STAC) Cohort. Journal of Thrombosis and Haemostasis. 2017; 15 (8): 1567–1575. DOI: https://doi.org/10.1111/jth.13752
16. Gran O.V., Smit E.N., Brækkan S.K., et al. Joint effects of cancer and variants in the factor 5 gene on the risk of venous thromboembolism. Haematologica. 2016; 101 (9): 1046–1053. DOI: https://doi.org/10.3324/haematol.2016.147405
17. Ahlbrecht J., Dickmann B., Ay C., et al. Tumor grade is associated with venous thromboembolism in patients with cancer: results from the Vienna Cancer and Thrombosis Study. Journal of Clinical Oncology. 2012; 30 (31): 3870–3875. DOI: https://doi.org/10.1200/JCO.2011.40.1810
18. Faiz A.S., Khan I., Beckman M.G., et al. Characteristics and risk factors of cancer associated venous thromboembolism. Thrombosis Research. 2015; 136 (3): 535–541. DOI: https://doi.org/10.1016/j.thromres.2015.06.036
19. Faiz A.S., Guo S., Kaveney A., et al. Venous thrombosis and breast cancer in older women: racial differences in risk factors and mortality. Thrombosis Research. 2018; 171: 130–135. DOI: https://doi.org/10.1016/j.thromres.2018.10.002
20. Huang J., Yang Z., Zhang J., et al. Analysis about the high risk factors and prognosis of gynecologic cancer with deep venous thrombosis. Zhonghua Fu Chan Ke Za Zhi. 2015; 50 (10): 762–769.
21. Khorana A.A., Dalal M., Lin J., Connolly GC. Incidence and predictors of venous thromboembolism (VTE) among ambulatory high-risk cancer patients undergoing chemotherapy in the United States. Cancer. 2013; 119 (3): 648–655. DOI: https://doi.org/10.1002/cncr.27772
22. Li Q., Xue Y., Peng Y., Li L. Analysis of risk factors for deep venous thrombosis in patients with gynecological malignant tumor: a clinical study. Pakistan Journal of Medical Sciences. 2019; 35 (1): 195–199. DOI: https://doi.org/10.12669/pjms.35.1.365
23. Bleau N., Patenaude V., Abenhaim H.A. Risk of venous thrombo-embolic events in pregnant patients with cancer. Journal of Maternal-Fetal and Neonatal Medicine. 2016; 29 (3): 380–384. DOI: https://doi.org/10.3109/14767058.2015.1009439
24. Farge D., Bounameaux H., Bauersachs R.M., et al. Women, thrombosis, and cancer: A gender-specific analysis. Thrombosis Research. 2017; 151 (1): 21–29. doi: 10.1016/S0049-3848(17)30062-2
25. Hase E.A., Barros V.I.P.V.L., Igai A.M.K., et al. Risk assessment of venous thromboembolism and thromboprophylaxis in pregnant women hospitalized with cancer: preliminary results from a risk score. Clinics (Sao Paulo). 2018; 73: 368. DOI: https://doi.org/10.6061/clinics/2018/e368
26. Seng S., Liu Z., Chiu S.K., et al. Risk of venous thromboembolism in patients with cancer treated with Cisplatin: a systematic review and meta-analysis. Journal of Clinical Oncology. 2012; 30 (35): 4416–4426. DOI: https://doi.org/10.1200/JCO.2012.42.4358
27. Debbie Jiang M.D., Alfred Ian Lee M.D. Thrombotic risk from chemotherapy and other cancer therapies. Cancer Treatment and Research. 2019; 179: 87–101. DOI: https://doi.org/10.1007/978-3-030-20315-3_6
28. Walker A.J., West J., Card T.R., et al. When are breast cancer patients at highest risk of venous thromboembolism? A cohort study using English health care data. Blood. 2016; 127 (7): 849–857. DOI: https://doi.org/10.1182/blood-2015-01-625582
29. Xu X., Chlebowski R.T., Shi J., et al. Aromatase inhibitor and tamoxifen use and the risk of venous thromboembolism in breast cancer survivors. Breast Cancer Research and Treatment. 2019; 174 (3): 785–794. DOI: https://doi.org/10.1007/s10549-018-05086-8
30. Yu I., Chen L., Ruan J.Y., et al. Risk and management of venous thromboembolisms in bevacizumab-treated metastatic colorectal cancer patients. Supportive Care in Cancer. 2016; 24 (3): 1199–1208. DOI: https://doi.org/10.1007/s00520-015-2899-y
31. Elice F., Rodeghiero F., Falanga A., Rickles F.R. Thrombosis associated with angiogenesis inhibitors. Best Practice & Research Clinical Haematology. 2009; 22 (1): 115–128. DOI: https://doi.org/10.1016/j.beha.2009.01.001
32. Choueiri T.K., Schutz F.A., Je Y., et al. Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. Journal of Clinical Oncology. 2010; 28 (13): 2280–2285. DOI: https://doi.org/10.1200/JCO.2009.27.2757
33. Kunimasa K., Nishino K., Kimura M., et al. Pembrolizumab-induced acute thrombosis: a case reporte. Medicine. 2018; 10772. doi: 10.1097/MD.0000000000010772
34. Ando Y., Hayashi T., Sugimoto R., et al. Risk factors for cancer-associated thrombosis in patients undergoing treatment with immune checkpoint inhibitors. Investigational New Drugs. 2020; 38 (4): 1200–1206. DOI: https://doi.org/10.1007/s10637-019-00881-6
35. Boone B.A., Zenati M.S., Rieser C., et al. Risk of venous thromboembolism for patients with pancreatic ductal adenocarcinoma undergoing preoperative chemotherapy followed by surgical resection. Annals of Surgical Oncology. 2019; 26 (5): 1503–1511. DOI: https://doi.org/10.1245/s10434-018-07148-z
36. Khorana A.A., Kuderer N.M., Culakova E., et al. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 2008; 111 (10): 4902–4907. DOI: https://doi.org/10.1182/blood-2007-10-116327
37. Guy J.B., Bertoletti L., Magné N., et al. RIETE investigators. Venous thromboembolism in radiation therapy cancer patients: Findings from the RIETE registry. Critical Reviews in Oncology/Hematology. 2017; 113: 83–89. DOI: https://doi.org/10.1016/j.critrevonc.2017.03.006
38. Bosco C., Garmo H., Adolfsson J., et al. Prostate cancer radiation therapy and risk of thromboembolic events. International Journal of Radiation Oncology, Biology, Physics. 2017; 97 (5): 1026–1031. DOI: https://doi.org/10.1016/j.ijrobp.2017.01.218
39. Chen L., Eloranta S., Martling A., et al. Short- and long-term risks of cardiovascular disease following radiotherapy in rectal cancer in four randomized controlled trials and a population-based register. Radiotherapy and Oncology. 2018; 126 (3): 424–430. DOI: https://doi.org/10.1016/j.radonc.2017.12.008
40. Cherkashin M., Berezina N., Vorobyov N., Pinelis E. Venous thromboembolism in radiation oncology: retrospective trial. Radiotherapy and Oncology. 2017; 123 (Suppl 1): 754–755. DOI: https://doi.org/10.1016/S0167-8140(17)31865-0
41. Temraz S., Moukalled N., Gerotziafas G.T., et al. Association between radiotherapy and risk of cancer associated venous thromboembolism: a sub-analysis of the COMPASS-CAT Study. Cancers (Basel). 2021; 13 (5): 1033. DOI: https://doi.org/10.3390/cancers13051033
42. Guy J.B., Falk A.T., Chargari C., et al. Thromboembolic events following brachytherapy: case reports. Journal of Contemporary Brachytherapy. 2015; 7 (1): 76–78. DOI: https://doi.org/10.5114/jcb.2015.48580
43. Bellini G., Teng A., Kotecha N., et al. The identification of risk factors for venous thromboembolism in gastrointestinal oncologic surgery. Journal of Surgical Research. 2016; 205 (2): 279–285. DOI: https://doi.org/10.1016/j.jss.2016.06.089
44. Xie Y.Z., Fang K., Ma W.L., Shi Z.H. Risk of postoperative deep venous thrombosis in patients with colorectal cancer treated with open or laparoscopic colorectal surgery: a meta-analysis. Indian Journal of Cancer. 2015; 51 (2): 42–44. DOI: https://doi.org/10.4103/0019-509X.151992
45. Gaddh M., Antun A., Yamada K., et al. Venous access catheter-related thrombosis in patients with cancer. Leukemia & Lymphoma. 2014; 55 (3): 501–508. DOI: https://doi.org/10.3109/10428194.2013.813503
46. Ellis M.L., Okano S., McCann A., et al. Catheter-related thrombosis incidence and risk factors in adult cancer patients with central venous access devices. Internal Medicine Journal. 2020; 50 (12): 1475–1482. DOI: https://doi.org/10.1111/imj.14780